LATEST UPDATES » Vol 26, Nos. 09 & 10, September & October 2022 – Toxins and Medicines – Two Sides of the Same Coin       » Utilising Metal Nanoparticles as Plant Growth Regulators to Improve Crop Yield       » Remedy or Poison? How Microplastics Influence Copper Ion Toxicity in Aquatic Plants       » Synthesising Schiff Base Antimicrobial Copper Complexes With Unprecedented Speed       » Enhancing the Understanding of Past Infections With Machine Learning       » Mini, Cellular Bioweapons: Understanding the Structure and Mechanism of Stinging in Sea Anemone Nematocysts       » Converting Dead Spiders Into Gripping Tools
Vol 24, No. 10, October 2020   |   Issue PDF view/purchase
Joint Efforts to Accelerate Development of Targeted Cancer Therapies
AUM Biosciences together with A*STAR’s Singapore Immunology Network (SIgN) establish a new joint lab in Singapore, focussing on drug development and immune-monitoring of novel oncology drugs.

Cancer remains a major medical concern with one in every six deaths being related to the disease. Recent disruptive discoveries in cancer therapy have highlighted the critical role of targeting the host immune system in regulating cancer progression.

AUM Biosciences is an oncology-focused biotechnology company based in Singapore, it aims to boost the development of innovative, and affordable cancer medicines for oncology patients in Asia and across the world. In an announcement in August 2020, AUM Biosciences has teamed up with SIgN to construct a new joint lab for the development of novel therapeutics in oncology. This new lab will be established at Biopolis, Singapore’s biomedical research hub, where SIgN is currently located.

The joint lab will focus on the discovery of novel and proprietary immune biomarkers and understanding of drug mechanisms of action that can be translated to better clinical trial design and study endpoint analysis.

Professor Lam Kong Peng, Executive Director of SIgN, added, “We are excited to bring SIgN’s expertise in translational immunology to the joint lab to help accelerate the development of novel cancer therapies, and to support Singapore’s vibrant biotech scene through our collaboration.”

Dr. Harish Dave, CMO of AUM Biosciences, stated “AUM Biosciences is delighted to partner with SIgN in this exciting public - private collaboration. This represents the coming together of the best in translational research and industry to meet a common goal of delivering effective cancer therapeutics to patients.”

This collaboration will bring together the scientific expertise of SIgN in translational immunology, preclinical, and computational research and AUM Bioscience’s extensive capabilities in clinical trial design and management for improved targeted development programs for cancer therapies.

The timely partnership will synergize drug development and immune profiling efforts to advance the development of multiple small molecules through preclinical and clinical trials with the ultimate goal of bringing novel targeted oncology therapeutics to the market.


What Has Covid Ever Done for Us?
news 2022 PDA Aseptic Processing of Biopharmaceuticals Conference
news Thailand LAB INTERNATIONAL, Bio Asia Pacific, and FutureCHEM INTERNATIONAL are ready to offer the Science and Technology Industry complete solutions this September!
news Better together: registration opens for Vitafoods Asia 2022 co-located with Fi Asia in October
news 2022 PDA Pharmaceutical Manufacturing & Quality Conference

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy